X-37

The core of X-37's strategy is its partnership with Atomwise, utilizing its AI platform to screen vast libraries of chemical compounds against high-value pharmaceutical targets. This technology-driven approach aims to accelerate the identification of potent and selective small molecules for proteins considered difficult to drug. The company's development pipeline is focused on significant unmet clinical needs, with programs targeting ZAP-70 for autoimmune diseases, PIM3 and SHP2 for cancer, and Factor XIIa for anticoagulation. By the end of 2019, X-37 had successfully secured $14.5 million in a Series A financing round led by DCVC Bio, with participation from Alpha Intelligence Capital and Hemi Ventures, to advance its drug leads through preclinical testing.

X-37 operates with a distinct business model structured to optimize its development and exit strategies. Each drug development program is housed in a separate virtual company under a parent LLC. This tax-efficient and flexible structure allows the company to divest or partner individual drug programs with major pharmaceutical companies once they reach a medically-relevant inflection point, without affecting the parent entity. This model positions X-37 to collaborate with large pharma for late-stage development and commercialization, thereby focusing its internal expertise on the early, AI-powered discovery and preclinical phases.